Skip to content

Allergan Recognized for Energy Management

Allergan Recognized for Energy Management

The Environmental Protection Agency (EPA) has recognized Allergan’s manufacturing plant as one of the first four pharmaceutical plants to be awarded the EPA’s Energy Star. Compared to similar pharmaceutical plants across the country, Allergan’s Texas plant uses nearly 35 percent less energy during its manufacturing process.

Read more here  >

Allergan Recognized for Energy Management

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (Botulinum Toxin Type A), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (Botulinum Toxin Type A), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Throughout our Web site you can learn more about these and our full portfolio of products.

AGN NYSE
46.84 (-0.61)
Volume 3,041,300

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

06.18.09Allergan Receives FDA Approval for OZURDEX Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease
05.26.09Allergan Receives Complete Response Letter for BOTOX(R) (Botulinum Toxin Type A) for Treatment of Upper Limb Spasticity in Adults
05.15.09VIDEO: Allergan, Inc. Announces the 'BOTOX(R) Cosmetic: Express Success' Charitable Education Campaign, Committing $250,000 to the Not-For-Profit Dress for Success
More news